missing translation for 'onlineSavingsMsg'
Learn More
Learn More
HLA DRA Antibody (169-1B5.2), Alexa Fluor™ 750, Novus Biologicals™
Mouse Monoclonal Antibody
Brand: Novus Biologicals NBP2-47722AF750
This item is not returnable.
View return policy
Description
HLA DRA Monoclonal specifically detects HLA DRA in Human, Bovine, Feline samples. It is validated for Flow Cytometry, Immunocytochemistry/Immunofluorescence, Immunofluorescence.
Specifications
| HLA DRA | |
| Monoclonal | |
| Alexa Fluor 750 | |
| 50 mM sodium borate with 0.05% sodium azide | |
| HLA-DRA | |
| Human peripheral blood leukocytes (Uniprot: P01903) | |
| Primary | |
| This antibody detects a monomorphic general framework determinant of HLA-DR Class II antigen. It does not cross react with HLA-DP and HLA-DQ. HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36kDa alpha (heavy) chain and a 28kDa beta (light) chain. It is expressed on B-cells, activated T-cells, monocytes/macrophages, dendritic cells and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is critical for efficient peptide presentation to CD4+ T cells. It is an excellent histiocytic marker in paraffin sections producing intense cytoplasmic staining. True histiocytic neoplasms are similarly positive. HLA-DR antigens also occur on a variety of epithelial cells and their corresponding neoplastic counterparts. | |
| Store at 4°C in the dark. |
| Flow Cytometry, Immunofluorescence | |
| 169-1B5.2 | |
| Flow Cytometry, Immunofluorescence | |
| FLJ51114, histocompatibility antigen HLA-DR alpha, HLA class II histocompatibility antigen, DR alpha chain, HLA-DRA1, major histocompatibility complex, class II, DR alpha, MHC cell surface glycoprotein, MHC class II antigen DRA, MLRW | |
| Mouse | |
| 0.1 mL | |
| 3122 | |
| Human, Bovine, Feline | |
| IgG2b κ |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction